0 Uncategorized - March 8, 2025Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AADFive times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also […]Read More
0 Uncategorized - March 8, 2025Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in PsoriasisESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and […]Read More
0 Uncategorized - March 8, 2025Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del ejercicio 2024– Una vez finalizada la inscripción a VIRAGE, el ensayo clínico de Fase 2b de VCN-01 para el adenocarcinoma pancreático […]Read More
